Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Its high debt load remained a cause of investor concern for the entire year, and as a result, CEO Albert Bourla’s turnaround strategy is now a key part of Pfizer Inc. (NYSE:PFE)’s hypothesis.

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

CEO Albert Bourla said the company’s dispute with activist firm Starboard Value isn’t “an aggressive situation,” months after the ...

From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...

Purchase of Intra-Cellular will give J&J control of mental health drug Caplyta, which CEO predicts will become a $5 billion ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla ...